ENLIGHTEN Study

Study Describing Cognitive Processing Speed Changes In Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

Nerve cell attacked by Antibodies

AGE: 18 to 80 years
SEX AT BIRTH: All
TYPE: Investigational Drug Study
CONDITION: Relapsing-remitting multiple sclerosis (RRMS)
HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center

Learn More About This Research Study

For more information, please contact study coordinator, Eileen Terrell at 216-844-1800 (ext 3) or complete the online form below.

Study Purpose

The purpose of this study is to learn about changes in cognition that happen while being treated with the study drug ozanimod, taken by mouth for the treatment of RMS.

Who Can Participate

Participants diagnosed with relapsing multiple sclerosis may be eligible for this study.

Request More Information

To learn more about this study, please fill out the form below to request more information.

XXX-XXX-XXXX

STUDY ID#